Karyopharm Therapeutics Inc. (KPTI) stock forecast & analysis
0.6620
NasdaqGS · USDDelayed by 15 minutes
Down: -0.2178, -24.8%
0.6538Down: -0.0082, -1.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.9020
- Previous close
- 0.8798
- Day range
- 0.5868 – 0.9020
- 52-week range
- 0.3100 – 10.99
- Volume (shares)
- 3.45M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 22.68M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.04
- Market cap
- 15.02M
Market Scanner’s AI analysis of Karyopharm Therapeutics Inc. (KPTI), updated October 2026: Karyopharm Therapeutics' revenue decline and negative margins contrasted with short-term price volatility
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Karyopharm Therapeutics Inc. (KPTI) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Karyopharm Therapeutics' revenue decline and negative margins contrasted with short-term price volatility
Recent analyses for Karyopharm Therapeutics (KPTI) covered its financial performance, noting a year-over-year revenue decrease of 11.9% in the latest quarter and significant negative net and operating margins. The stock has experienced substantial short-term price increases alongside longer-term declines, with technical indicators showing mixed signals regarding momentum and overbought conditions.
KPTI technical picture
KPTI's stock price showed significant short-term volatility, with a sharp recent increase but substantial longer-term declines. Technical indicators presented a mixed picture: momentum readings were neutral, but the Money Flow Index suggested overbought conditions while the MACD signaled bearish momentum. The price traded below key moving averages and within the Bollinger Bands.
Fundamentals
Karyopharm Therapeutics (KPTI) reported a year-over-year revenue decrease in its latest quarterly results. The company's net and operating margins were significantly negative, with substantial losses reported for the fiscal year and the most recent quarter.
Factors discussed — upside
- Strong buying pressure indicated by Money Flow Index (MFI) in overbought territory
- Substantial short-term price increase of +96.2% over 7 days
Factors discussed — risks
- Year-over-year quarterly revenue decrease of 11.9%
- Negative net profit margin of -153.3% and operating margin of -56.2% TTM
- Significant net loss reported for the fiscal year 2025 and the most recent quarter
- Stock trading significantly below its 50-day and 200-day SMAs
- Bearish momentum signaled by MACD below zero
- Revenue trends
- Profitability metrics
- Technical indicators
- Short-term price volatility
Summary updated .
KPTI technical indicators
Common technical indicators for KPTI, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.22 | Price below |
| 10-day exponential moving average | 0.62 | Price above |
| Relative strength index (14-day) | 42.99 | Neutral |
| MACD line (12/26/9) | -0.1940 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.23 – 0.84 | Price inside the bands |
Analyses
Recent KPTI.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-29 KPTI.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Karyopharm Therapeutics Inc.?
- The analyses noted strong buying pressure indicated by the Money Flow Index and a substantial short-term price increase of over 96% in the past week.
- What are the risks for Karyopharm Therapeutics Inc.?
- Risks discussed include an 11.9% year-over-year decrease in quarterly revenue, significant negative profit and operating margins, and substantial net losses reported for both the past fiscal year and the most recent quarter. The stock is also trading below its key moving averages, with bearish momentum signaled by the MACD.
- Is Karyopharm Therapeutics Inc. bullish or bearish?
- Recent AI analyses of Karyopharm Therapeutics Inc. examined factors on both sides. Discussed upside: The analyses noted strong buying pressure indicated by the Money Flow Index and a substantial short-term price increase of over 96% in the past week. Discussed risks: Risks discussed include an 11.9% year-over-year decrease in quarterly revenue, significant negative profit and operating margins, and substantial net losses reported for both the past fiscal year and the most recent quarter. The stock is also trading below its key moving averages, with bearish momentum signaled by the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Karyopharm Therapeutics Inc.?
- Recent analyses for Karyopharm Therapeutics (KPTI) covered its financial performance, noting a year-over-year revenue decrease of 11.9% in the latest quarter and significant negative net and operating margins. The stock has experienced substantial short-term price increases alongside longer-term declines, with technical indicators showing mixed signals regarding momentum and overbought conditions.
- How does Market Scanner analyse Karyopharm Therapeutics Inc.?
- Every analysis of Karyopharm Therapeutics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Karyopharm Therapeutics Inc.?
The analyses noted strong buying pressure indicated by the Money Flow Index and a substantial short-term price increase of over 96% in the past week.
What are the risks for Karyopharm Therapeutics Inc.?
Risks discussed include an 11.9% year-over-year decrease in quarterly revenue, significant negative profit and operating margins, and substantial net losses reported for both the past fiscal year and the most recent quarter. The stock is also trading below its key moving averages, with bearish momentum signaled by the MACD.
Is Karyopharm Therapeutics Inc. bullish or bearish?
Recent AI analyses of Karyopharm Therapeutics Inc. examined factors on both sides. Discussed upside: The analyses noted strong buying pressure indicated by the Money Flow Index and a substantial short-term price increase of over 96% in the past week. Discussed risks: Risks discussed include an 11.9% year-over-year decrease in quarterly revenue, significant negative profit and operating margins, and substantial net losses reported for both the past fiscal year and the most recent quarter. The stock is also trading below its key moving averages, with bearish momentum signaled by the MACD. These are descriptive observations, not a recommendation.
What is the latest sentiment on Karyopharm Therapeutics Inc.?
Recent analyses for Karyopharm Therapeutics (KPTI) covered its financial performance, noting a year-over-year revenue decrease of 11.9% in the latest quarter and significant negative net and operating margins. The stock has experienced substantial short-term price increases alongside longer-term declines, with technical indicators showing mixed signals regarding momentum and overbought conditions.
How does Market Scanner analyse Karyopharm Therapeutics Inc.?
Every analysis of Karyopharm Therapeutics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh KPTI.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.